News

“As well as the 250A hour version we make a 125A hour one, which gives a 24V output; and the next one up from the 250 is the 500A hour, which has all the same characteristics but is just a little bit ...
Building on Ascletis’ positive Phase 3 results, Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned ...
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to ...
We report the interim analysis of efficacy and safety outcomes of Padeliporfin VTP for treatment of LG UTUC in ENLIGHTED, a Phase 3 trial (NCT04620239). Methods: This is an open-label phase 3 study ...
The first phase of Honkai Star Rail 3.3 is nearing its end, and Trailblazers are eagerly waiting for the upcoming 5-star unit, Cipher. Your login session has expired.
AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival (PFS) in a phase 3 breast ...
WATERTOWN, Mass. - Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage biotechnology company, today announced successful outcomes from its ENLIGHTEN 2 Phase 3 clinical trial for LYR-210, a ...
Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3 ...
The Phase 3 VERIFY study (NCT05210790) is an ongoing, three-part, global, randomized, placebo-controlled study evaluating rusfertide in 293 patients with polycythemia vera over a 156-week period.
BAAR, Switzerland, May 31, 2025--Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented ...
We conducted an international, randomized, phase 3 trial comparing second-line trastuzumab deruxtecan at a dose of 6.4 mg per kilogram of body weight with ramucirumab plus paclitaxel in patients ...